Figures & data
Figure 2. Proportion of articles within each theme. A, Epidemiology; B, Models; C, Studies in animals; D, Mechanisms; E, Assessment and prognosis; F, Pharmacotherapy; G, Neuromodulation; H, Sensory therapies; I, Clinical practice. TCD–Thalamocortical Dysrhythmia, OTO-313–a sustained-exposure formulation of gacyclidine, ARI–acoustic residual inhibition.
![Figure 2. Proportion of articles within each theme. A, Epidemiology; B, Models; C, Studies in animals; D, Mechanisms; E, Assessment and prognosis; F, Pharmacotherapy; G, Neuromodulation; H, Sensory therapies; I, Clinical practice. TCD–Thalamocortical Dysrhythmia, OTO-313–a sustained-exposure formulation of gacyclidine, ARI–acoustic residual inhibition.](/cms/asset/a5656c1f-1380-4eeb-b3c5-2f327188af43/tnzr_a_2363424_f0002_oc.jpg)
Figure 3. Overview of different tinnitus models and how they are related to each other (De Ridder, Vanneste, Langguth, et al. Citation2015).
![Figure 3. Overview of different tinnitus models and how they are related to each other (De Ridder, Vanneste, Langguth, et al. Citation2015).](/cms/asset/67f1dff3-0140-4226-a4cc-18897dbf4031/tnzr_a_2363424_f0003_oc.jpg)